BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 15973445)

  • 21. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
    DeBenedette MA; Wen T; Bachmann MF; Ohashi PS; Barber BH; Stocking KL; Peschon JJ; Watts TH
    J Immunol; 1999 Nov; 163(9):4833-41. PubMed ID: 10528184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma.
    Hirschowitz EA; Naama HA; Evoy D; Lieberman MD; Daly J; Crystal RG
    Cancer Gene Ther; 1999; 6(6):491-8. PubMed ID: 10608345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
    Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
    Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
    Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
    J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antitumor immune responses induced by gene transfer of 4-1BBL into hepatocellular carcinoma Hepa1-6 in vitro].
    Liu CL; Dou KF; Zang XX; Zhu BF; Chen SM
    Zhonghua Wai Ke Za Zhi; 2004 May; 42(9):554-8. PubMed ID: 15196371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
    Müller D; Frey K; Kontermann RE
    J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy.
    Wang H; Dai J; Hou S; Qian W; Li B; Ma J; Fan X; Zhao J; Yang S; Sang H; Yang Q; Wang R; Guo Y
    Cancer Gene Ther; 2005 Sep; 12(9):769-77. PubMed ID: 15877081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.
    Siders WM; Wright PW; Hixon JA; Alvord WG; Back TC; Wiltrout RH; Fenton RG
    J Immunol; 1998 Jun; 160(11):5465-74. PubMed ID: 9605149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
    Ciavarra RP; Brown RR; Holterman DA; Garrett M; Glass WF; Wright GL; Schellhammer PF; Somers KD
    Cancer Immunol Immunother; 2003 Sep; 52(9):535-45. PubMed ID: 14627125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.
    Benihoud K; Esselin S; Descamps D; Jullienne B; Salone B; Bobé P; Bonardelle D; Connault E; Opolon P; Saggio I; Perricaudet M
    Gene Ther; 2007 Mar; 14(6):533-44. PubMed ID: 17109009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.
    Zhang J; Zhou Z; Wang C; Shen J; Zheng Y; Zhang L; Wang J; Xia D
    Cancer Immunol Immunother; 2011 Apr; 60(4):559-73. PubMed ID: 21240488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
    Zhang W; Yang H; Wang Z; Jim X
    Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity.
    Saito T; Takayama T; Osaki T; Nagai S; Suzuki T; Sato M; Kuwano H; Tahara H
    Cancer Sci; 2008 Oct; 99(10):2028-36. PubMed ID: 19016763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.
    Shi W; Siemann DW
    Anticancer Res; 2006; 26(5A):3445-53. PubMed ID: 17094465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study.
    Sui CG; Wu D; Meng FD; Yang MH; Jiang YH
    Genet Mol Res; 2015 Jun; 14(2):7208-17. PubMed ID: 26125931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.